reboxetine has been researched along with idazoxan in 7 studies
Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (idazoxan) | Trials (idazoxan) | Recent Studies (post-2010) (idazoxan) |
---|---|---|---|---|---|
626 | 193 | 184 | 1,499 | 40 | 123 |
Protein | Taxonomy | reboxetine (IC50) | idazoxan (IC50) |
---|---|---|---|
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0083 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0195 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0195 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0537 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0195 | |
Alpha-1A adrenergic receptor | Homo sapiens (human) | 2.884 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0195 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bernini, M; Bianchetti, A; Invernizzi, RW; Parini, S; Sacchetti, G; Samanin, R | 1 |
Frazer, A; Gould, GG; Morilak, DA; Pardon, MC | 1 |
Conklin, D; Eisenach, JC; Obata, H | 1 |
Chang, ST; Chuang, CH; Kao, YC; Lin, YL; Liu, YP; Tung, CS | 1 |
Connor, TJ; González-Reyes, RE; Griffin, EW; Harkin, A; McNamee, EN; Ryan, KJ; Ryan, KM | 1 |
Artigas, F; Bortolozzi, A; Masana, M | 1 |
Borgkvist, A; Feltmann, K; Lindskog, M; Malmlöf, T; Schilström, B | 1 |
7 other study(ies) available for reboxetine and idazoxan
Article | Year |
---|---|
Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Biogenic Monoamines; Brain; Clonidine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Space; Frontal Lobe; Hippocampus; Idazoxan; Male; Microdialysis; Morpholines; Norepinephrine; Rats; Rats, Sprague-Dawley; Reboxetine; Serotonin; Sodium Chloride; Time Factors | 1999 |
Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Autoradiography; Binding Sites; Brain; Brain Mapping; Carrier Proteins; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Interactions; Idazoxan; In Situ Hybridization; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Adrenergic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Symporters; Time Factors; Tissue Distribution; Tyrosine 3-Monooxygenase | 2003 |
Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Atropine; Behavior, Animal; Disease Models, Animal; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drosophila Proteins; Drug Interactions; Hyperalgesia; Idazoxan; Male; Morpholines; Muscarinic Antagonists; Pain Threshold; Pain, Postoperative; Peptides; Rats; Rats, Sprague-Dawley; Reboxetine; Snail Family Transcription Factors; Spinal Cord; Time Factors; Transcription Factors | 2005 |
Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Attention; Discrimination, Psychological; Drug Evaluation, Preclinical; Drug Interactions; Feeding Behavior; Idazoxan; Impulsive Behavior; Male; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Prazosin; Rats; Rats, Sprague-Dawley; Reaction Time; Reboxetine; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Spatial Behavior; Time Perception | 2009 |
Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Animals; Brain; Cerebral Cortex; Clenbuterol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hippocampus; Idazoxan; Injections, Intraperitoneal; Interleukin-10; Interleukin-4; Male; Morpholines; Norepinephrine; Phosphorylation; Propranolol; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Adrenergic, beta; Receptors, Adrenergic, beta-2; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Transforming Growth Factor beta | 2010 |
Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
Topics: Adrenergic Agents; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Electric Stimulation; Haloperidol; Idazoxan; Male; Microdialysis; Molecular Targeted Therapy; Morpholines; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Wistar; Reboxetine; Schizophrenia; Synaptic Transmission; Ventral Tegmental Area | 2011 |
Dopamine in the hippocampus is cleared by the norepinephrine transporter.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Cocaine; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Administration Routes; Drug Interactions; Hippocampus; Idazoxan; Male; Microdialysis; Morpholines; Nomifensine; Norepinephrine Plasma Membrane Transport Proteins; Raclopride; Rats; Rats, Wistar; Reboxetine; Sodium Channel Blockers; Tetrodotoxin; Time Factors; Wakefulness | 2012 |